menu

CME: Advancing Care in Gastrointestinal Cancers: A Refreshed View of ASCO 2019

Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

Advancing Care in Gastrointestinal Cancers

Advancing Care in Gastrointestinal Cancers
RestartResume
In this clinical countdown discussion, two oncologists need to beat the clock to share clinical trial data that may impact how we manage GI cancers.

Available credits: 0.25

Time to complete: 15 minutes

Released:

Valid until:

Take Post-Test

If you’ve already completed the activity.

  • Overview

    As new evidence continues to be published and presented at scientific conferences, oncologists are finding it more difficult to stay on top of new information. That’s why Drs. Eileen O'Reilly and Paul Oberstein are here to review selected abstracts from the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting… but the catch is that they only have 3 minutes to cover each update in this clinical countdown discussion. Can they beat the clock?

  • Disclosure of Conflicts of Interest

    In accordance with the ACCME Standards for Commercial Support, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. GLC resolves all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.

    Host:

    Paul Obserstein, MD
    Assistant Professor of Medicine & Director of GI Oncology
    NYU Langone Perlmutter Comprehensive Cancer Center
    New York, NY

    Consulting Fees:  BTG, Ipsen, Merck, Tyme

    Faculty:

    Eileen O'Reilly, MD
    Associate Attending Physician
    Director of Clinical Research at Memorial Sloan Kettering Cancer Center
    New York, NY

    Consulting Fees: Agios, Astra Zeneca, Bayer, Beigene, Bioline, BMS, Celgene, CytomX, Debio, Eisai, Exelixis,
    Flatiron, Genoscience, Incyte, Ipsen, Jansen, LAM, Lilly, Loxo, Merck, MINA, Pfizer, QED, Redhill, Sanofi, Silenseed, Sillajen, Sobi, Targovax, Vicus, Yiviva                                               

    Contracted Research: ActaBiologica, Astra Zeneca, BMS, Celgene, Genentech, Halozyme, Mabvax, Roche, Silenseed

    Reviewers/Content Planners/Authors:

    • Ann Early has nothing to disclose.
    • Barry Fiedel, PhD has nothing to disclose.
    • Nick Lombardi has ownership interest in Vertex Pharmacueticals.
    • Madison Tamburini has nothing to disclose.
  • Learning Objectives

    After participating in this educational activity, participants should be better able to:

    • Identify key clinical trial data that may positively impact the treatment and management of GI cancers (Pancreatic, Colorectal, Esophageal, and Hepatobiliary Cancers)
    • Apply emergent data to patient care scenarios to facilitate translation of scientific evidence to clinical practice
  • Target Audience

    This activity is designed to meet the educational needs of oncologists, hematologists, oncology nurses, and gastroenterologists.

  • Accreditation and Credit Designation Statements

    Global Learning Collaborative is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    Global Learning Collaborative designates this enduring material for a maximum of .25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

  • Provider(s)/Educational Partner(s)

    Prova Education, designs and executes continuing education founded on evidence-based medicine, clinical need, gap analysis, learner feedback, and more. Our mission is to serve as an inventive and relevant resource for clinical content and educational interventions across a broad spectrum of specialties. 

    Prova Education's methodology demonstrates a commitment to continuing medical education and the innovative assessment of its effects. Our goal is clear—to develop and deliver the very best education in the most impactful manner and to verify its results with progressive outcomes research.

  • Commercial Support

    This activity is supported by an independent educational grant from Merck & Co., Inc. and Celgene.

  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and Prova Education. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to link to a site outside of Prova Education you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.

    Reproduction Prohibited

    Reproduction of this material is not permitted without written permission from the copyright owner.

  • System Requirements

    Our site requires a computer, tablet or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/cable). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Internet Explorer, Microsoft Edge, Chrome, Firefox or Safari. Users accustomed to IE8, IE9 IE10 are advised to update their browsers for the best experience.

Facebook Comments

LIVE ON REACHMD RADIOBack to live radio

Loading...

Programs 12/10/19